July 26, 2018 – By Ronnie Lemelle
Homrich & Berg increased Amazon Com Inc (AMZN) stake by 14.32% reported in 2018Q1 SEC filing. Homrich & Berg acquired 266 shares as Amazon Com Inc (AMZN)âs stock rose 5.80%. The Homrich & Berg holds 2,123 shares with $3.07M value, up from 1,857 last quarter. Amazon Com Inc now has $878.14B valuation. The stock decreased 2.89% or $53.87 during the last trading session, reaching $1809.74. About 6.27 million shares traded or 57.90% up from the average. Amazon.com, Inc. (NASDAQ:AMZN) has risen 62.09% since July 26, 2017 and is uptrending. It has outperformed by 49.52% the S&P500. Some Historical AMZN News: 07/05/2018 â Tim Stone, Longtime Amazon Executive, to Join Snap as CFO Starting May 16; 14/05/2018 â Amazonâs board of directors had initially opposed making changes to its existing board nomination policy; 20/03/2018 â Yahoo! UK: Exclusive â On Amazon, a quarter of merchantsâ sales are cross-border; 05/03/2018 â ChainStore [Reg]: Report: Amazon stops selling Googleâs Nest smart home lineâbut not by choice; 24/04/2018 â BEZOS SAYS AMAZON WILL FOLLOW ANY REGULATION FOR TECH COS; 19/04/2018 â Amazonâs 100 million Prime members will help it become the No. 1 apparel retailer in the US; 22/05/2018 â Child Transportation Provider Z M Hires Former Amazon Executive Roie Chizik as CFO; 12/03/2018 â Hop-on expands Online Stores, Amazon, NaturallyCedar.com and Shop CBD Online; 07/04/2018 â Postmates and DoorDash have discussed a merger to fend off Uber, GrubHub and Amazon:; 20/03/2018 â Metro Ottawa: Amazon considering buying some U.S. Toys âRâ Us stores
Among 9 analysts covering Amgen Inc (NASDAQ:AMGN), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Amgen Inc had 12 analyst reports since February 1, 2018 according to SRatingsIntel. The rating was downgraded by Atlantic Securities to âHoldâ on Monday, February 5. The firm has âOverweightâ rating by Morgan Stanley given on Wednesday, April 25. Cowen & Co maintained the stock with âBuyâ rating in Thursday, February 1 report. The stock of Amgen Inc. (NASDAQ:AMGN) earned âOverweightâ rating by Morgan Stanley on Friday, July 13. Credit Suisse maintained Amgen Inc. (NASDAQ:AMGN) rating on Friday, February 2. Credit Suisse has âNeutralâ rating and $194 target. The rating was maintained by Piper Jaffray with âBuyâ on Thursday, February 1. The firm has âMarket Performâ rating given on Friday, February 2 by BMO Capital Markets. Barclays Capital maintained it with âEqual-Weightâ rating and $180 target in Thursday, April 5 report. The firm has âOverweightâ rating by PiperJaffray given on Friday, February 2. The firm has âOverweightâ rating by Morgan Stanley given on Friday, February 2. See Amgen Inc. (NASDAQ:AMGN) latest ratings:
13/07/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $200 New Target: $210 Maintain
25/04/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $205 New Target: $200 Maintain
05/04/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $190 New Target: $180 Maintain
12/03/2018 Broker: Morgan Stanley Rating: Buy New Target: $196.0
12/02/2018 Broker: Mizuho Rating: Buy New Target: $200.0 Maintain
05/02/2018 Broker: Atlantic Securities Rating: Hold Downgrade
01/02/2018 Broker: Cowen & Co Rating: Buy New Target: $204.0 Maintain
02/02/2018 Broker: Credit Suisse Old Rating: Neutral New Rating: Neutral Old Target: $191 New Target: $194 Maintain
02/02/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $192 New Target: $202 Maintain
02/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $204 New Target: $196 Maintain
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company has market cap of $128.07 billion. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. It has a 63.41 P/E ratio. The companyÃâs products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism ; and Erenumab for the prevention of migraine.
More notable recent Amgen Inc. (NASDAQ:AMGN) news were published by: Benzinga.com which released: âNasdaq, Tech Names Might Come Under Pressure Following Facebookâs Weak Resultsâ on July 26, 2018, also Streetinsider.com with their article: âAmgen (AMGN) call put ratio 1.42 calls to 1 put into EPS and outlookâ published on July 26, 2018, Nasdaq.com published: âAbbVieâs Stock Is a Bargain After Falling 8% Last Weekâ on July 23, 2018. More interesting news about Amgen Inc. (NASDAQ:AMGN) were released by: Benzinga.com and their article: âBenzingaâs Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Holdâ published on July 26, 2018 as well as Seekingalpha.comâs news article titled: âAmgen facing hurdles from insurers for migraine med Aimovigâ with publication date: July 26, 2018.
The stock increased 0.26% or $0.5 during the last trading session, reaching $193.54. About 1.77M shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 14.68% since July 26, 2017 and is uptrending. It has outperformed by 2.11% the S&P500. Some Historical AMGN News: 17/05/2018 â Novartis and Amgen announce FDA approval of Aimovigâ¢ (erenumab-aooe), a novel treatment developed specifically for migraine p; 10/03/2018 â REGENERON, SANOFIâS PRALUENT CUTS HEART RISKS BY 15% IN STUDY; 24/04/2018 â Amgen 1Q Adj EPS $3.47; 11/05/2018 â Amgen Presenting at Bank of America Conference May 15; 05/04/2018 â ABBVIE REPORTS GLOBAL RESOLUTION OF HUMIRAÂ® (ADALIMUMAB) PATENT; 23/03/2018 â EU MEDICINES AGENCY RECOMMENDS APPROVAL OF AMGEN EUROPEâS BIOSIMILAR DRUG FOR TREATMENT OF BREAST AND GASTRIC CANCER; 26/03/2018 â COHERUS: DISTRICT CRT ACCEPTS RECOMMENDED AMGEN SUIT DISMISSAL; 10/03/2018 â Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam; 15/05/2018 â PFIZER INC â RETACRIT IS EXPECTED TO BE AVAILABLE IN U.S. AT A SIGNIFICANT DISCOUNT TO CURRENT WHOLESALER ACQUISITION COST OF EPOGEN AND PROCRIT; 30/04/2018 â Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLISÂ® (carfilzomib)
Since February 14, 2018, it had 0 insider buys, and 5 sales for $1.36 million activity. Harper Sean E had sold 1,525 shares worth $265,503.
Investors sentiment decreased to 0.88 in Q1 2018. Its down 0.34, from 1.22 in 2017Q4. It dropped, as 67 investors sold Amgen Inc. shares while 557 reduced holdings. 114 funds opened positions while 435 raised stakes. 502.72 million shares or 8.88% less from 551.71 million shares in 2017Q4 were reported. Berkshire Asset Mngmt Ltd Liability Pa reported 129,468 shares or 2.14% of all its holdings. Perritt Cap accumulated 2,941 shares. Hallmark Capital has 103,803 shares for 2.15% of their portfolio. Verition Fund Mgmt Llc stated it has 0.22% in Amgen Inc. (NASDAQ:AMGN). Moreover, Amica Mutual has 0.55% invested in Amgen Inc. (NASDAQ:AMGN) for 25,855 shares. Vnbtrust Association owns 0.18% invested in Amgen Inc. (NASDAQ:AMGN) for 1,832 shares. Pinebridge Invests Limited Partnership reported 0.61% stake. Hirtle Callaghan And Ltd owns 2,000 shares or 0.03% of their US portfolio. 24,564 are held by Farmers. Lakeview Capital Prns Lc has 4,634 shares. Livforsakringsbolaget Skandia Omsesidigt invested 0.34% in Amgen Inc. (NASDAQ:AMGN). First Citizens Financial Bank owns 10,756 shares for 0.25% of their portfolio. First Foundation Advsrs stated it has 4,678 shares or 0.04% of all its holdings. Reilly Herbert Faulkner Iii reported 29,277 shares. Burns J W Ny reported 20,208 shares or 0.88% of all its holdings.
Investors sentiment decreased to 1.08 in 2018 Q1. Its down 0.21, from 1.29 in 2017Q4. It dropped, as 73 investors sold AMZN shares while 659 reduced holdings. 173 funds opened positions while 614 raised stakes. 266.38 million shares or 4.87% less from 280.02 million shares in 2017Q4 were reported. Truepoint has invested 0% in Amazon.com, Inc. (NASDAQ:AMZN). Moreover, Alesco Advsr Limited Liability Company has 0.01% invested in Amazon.com, Inc. (NASDAQ:AMZN) for 179 shares. Front Barnett Associates Ltd Llc owns 9,913 shares for 2.41% of their portfolio. D Scott Neal holds 125 shares or 0.1% of its portfolio. Jpmorgan Chase & holds 3.92M shares. Meeder Asset Mgmt holds 11,455 shares. Washington Tru National Bank & Trust holds 0.24% or 1,166 shares in its portfolio. Mitchell Capital Management has invested 3.67% in Amazon.com, Inc. (NASDAQ:AMZN). Fragasso Group holds 0.07% of its portfolio in Amazon.com, Inc. (NASDAQ:AMZN) for 199 shares. Mycio Wealth Partners Lc accumulated 0.36% or 2,200 shares. Notis invested 0.32% of its portfolio in Amazon.com, Inc. (NASDAQ:AMZN). Eagle Advsr Llc owns 8,513 shares or 0.43% of their US portfolio. Smith Chas P Associate Pa Cpas reported 519 shares. Citadel Advsrs Ltd Liability accumulated 181,382 shares. Jones Lllp has 8,956 shares for 0.03% of their portfolio.
Among 35 analysts covering Amazon (NASDAQ:AMZN), 35 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Amazon had 60 analyst reports since January 30, 2018 according to SRatingsIntel. PiperJaffray maintained Amazon.com, Inc. (NASDAQ:AMZN) on Friday, February 2 with âOverweightâ rating. M Partners maintained it with âBuyâ rating and $1750 target in Wednesday, February 21 report. The stock of Amazon.com, Inc. (NASDAQ:AMZN) earned âOutperformâ rating by Credit Suisse on Friday, April 20. The firm earned âBuyâ rating on Tuesday, May 29 by M Partners. Jefferies maintained the shares of AMZN in report on Friday, February 2 with âBuyâ rating. The stock of Amazon.com, Inc. (NASDAQ:AMZN) has âOutperformâ rating given on Friday, April 27 by Wedbush. The rating was initiated by Telsey Advisory with âBuyâ on Monday, May 7. Evercore maintained it with âBuyâ rating and $1745.0 target in Friday, March 9 report. The stock of Amazon.com, Inc. (NASDAQ:AMZN) has âBuyâ rating given on Friday, February 2 by J.P. Morgan. Cowen & Co maintained Amazon.com, Inc. (NASDAQ:AMZN) rating on Tuesday, February 27. Cowen & Co has âBuyâ rating and $1700.0 target.
Since February 15, 2018, it had 0 insider buys, and 21 sales for $63.19 million activity. 1,985 Amazon.com, Inc. (NASDAQ:AMZN) shares with value of $2.90 million were sold by Jassy Andrew R. Shares for $387,475 were sold by WILKE JEFFREY A on Thursday, March 8. $686,439 worth of Amazon.com, Inc. (NASDAQ:AMZN) was sold by Reynolds Shelley on Tuesday, May 15. Blackburn Jeffrey M also sold $18.50M worth of Amazon.com, Inc. (NASDAQ:AMZN) on Thursday, February 15. On Thursday, February 15 Olsavsky Brian T sold $3.42M worth of Amazon.com, Inc. (NASDAQ:AMZN) or 2,333 shares. Zapolsky David also sold $3.03M worth of Amazon.com, Inc. (NASDAQ:AMZN) shares. The insider ALBERG TOM A sold 2,285 shares worth $3.35M.
More notable recent Amazon.com, Inc. (NASDAQ:AMZN) news were published by: Nasdaq.com which released: âAmazon (AMZN) Expands Whole Foods Delivery in New York Cityâ on July 25, 2018, also Nasdaq.com with their article: âIs Amazon (AMZN) Outperforming Other Retail-Wholesale Stocks This Year?â published on July 24, 2018, Thestreet.com published: â6 Reasons Amazon Is an Investorâs Dreamâ on July 24, 2018. More interesting news about Amazon.com, Inc. (NASDAQ:AMZN) were released by: Benzinga.com and their article: âAmazon Q2 Earnings Preview: What To Expectâ published on July 25, 2018 as well as Marketwatch.comâs news article titled: âNasdaq slumps as Facebook suffers biggest one-day drop everâ with publication date: July 26, 2018.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.